Roivant Sciences Ltd.

Equities

ROIV

BMG762791017

Market Closed - Nasdaq Other stock markets 02:30:00 23/01/2026 am IST			5-day change	1st Jan Change
22.97 ^USD	-0.04%		-3.53%	+5.85%

21/01	Zura Bio Announces Chief Executive Officer Changes, Effective January 21, 2026	CI
15/01	Roivant Sciences Insider Sold Shares Worth $4,384,000, According to a Recent SEC Filing	MT

Transcript : Roivant Sciences Ltd. - Analyst/Investor Day

Published on 12/12/2025 at 10:20 pm IST - Modified on 12/13/2025 at 04:10 am IST

S&P Capital IQ

Presenter Speech
Keyur Parekh (Executives)

Good morning, and thank you to those joining us in person on this cold New York morning. An equally warm welcome to those joining us virtually. My name is

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Roivant Sciences Ltd.

21/01	Zura Bio Announces Chief Executive Officer Changes, Effective January 21, 2026	CI
15/01	Roivant Sciences Insider Sold Shares Worth $4,384,000, According to a Recent SEC Filing	MT
13/01	Roivant Sciences Ltd. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 03:00 PM
02/01	Roivant Sciences Insider Sold Shares Worth $28,902,500, According to a Recent SEC Filing	MT
19/12	Roivant Sciences Insider Sold Shares Worth $39,065,213, According to a Recent SEC Filing	MT
19/12	Roivant Sciences Insider Sold Shares Worth $39,065,213, According to a Recent SEC Filing	MT
18/12	Roivant Sciences Insider Sold Shares Worth $37,723,200, According to a Recent SEC Filing	MT
12/12	Roivant Sciences Ltd. - Analyst/Investor Day
11/12	Roivant Sciences Fast-Tracks Key Drug Development Programs	MT
11/12	Markets Wanted a Party. The Economy Brought a Reality Check.
11/12	Roivant Highlights Continued Pipeline Progress and Outlook for Company's Next Phase of Growth At 2025 Investor Day	CI
11/12	Roivant highlights continued pipeline progress and outlook for company's next phase of growth at 2025 Investor Day	RE
10/12	Psivant Therapeutics, Inc. announced that it has received $47.5 million in funding from YK Bioventures, Samsara BioCapital LLC, Roivant Sciences Ltd., LSV Capital Management, LLC, Eurofarma Laboratórios S.A. and other investors	CI
24/11	Roivant Sciences Insider Sold Shares Worth $26,304,500, According to a Recent SEC Filing	MT
18/11	Roivant Sciences Ltd. Presents at Jefferies London Healthcare Conference 2025, Nov-18-2025 05:00 PM
18/11	Roivant Sciences Insider Sold Shares Worth $37,939,112, According to a Recent SEC Filing	MT
11/11	Roivant Sciences Ltd. Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference, Nov-11-2025 08:00 AM
11/11	Markets Seek Direction
11/11	Analyst recommendations: Coreweave, Duolingo, Lyft, Qualcomm, Tempus…
10/11	Roivant Sciences Ltd., Q2 2026 Earnings Call, Nov 10, 2025
10/11	Roivant Sciences Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025	CI
10/11	Roivant Sciences' Fiscal Q2 Net Loss Narrows, Revenue Falls	MT
10/11	Tranche Update on Roivant Sciences Ltd.'s Equity Buyback Plan announced on August 11, 2025.	CI
10/11	Stocks Gain Pre-Bell as Senate Moves One Step Further to End Government Shutdown	MT
10/11	Biopharma Roivant's Q2 income from operations misses	RE